These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12633529)

  • 21. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
    Chen Z; Wang C; Xu X; Feng W
    Value Health; 2009; 12 Suppl 3():S85-8. PubMed ID: 20586990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.
    Soysal T; Eskazan AE; Ar MC
    Expert Rev Hematol; 2014 Dec; 7(6):697-9. PubMed ID: 25292262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
    Mesa RA; Steensma DP; Hoyer J; Ketterling RP
    Br J Haematol; 2003 Oct; 123(2):366-7. PubMed ID: 14531922
    [No Abstract]   [Full Text] [Related]  

  • 24. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D; Muir J
    Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
    [No Abstract]   [Full Text] [Related]  

  • 25. Bcr-Abl inhibition as a modality of CML therapeutics.
    Buchdunger E; Matter A; Druker BJ
    Biochim Biophys Acta; 2001 Aug; 1551(1):M11-8. PubMed ID: 11553417
    [No Abstract]   [Full Text] [Related]  

  • 26. STI-571 in chronic myelogenous leukaemia.
    Tsao AS; Kantarijian H; Talpaz M
    Br J Haematol; 2002 Oct; 119(1):15-24. PubMed ID: 12358949
    [No Abstract]   [Full Text] [Related]  

  • 27. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
    Kimura S; Kako S; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Watanabe T; Kanda Y
    Leuk Res; 2011 Jan; 35(1):e11-2. PubMed ID: 20952061
    [No Abstract]   [Full Text] [Related]  

  • 29. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib.
    Heartin E; Walkinshaw S; Clark RE
    Leuk Lymphoma; 2004 Jun; 45(6):1307-8. PubMed ID: 15360020
    [No Abstract]   [Full Text] [Related]  

  • 31. Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
    Ostro D; Cheung K; Kamel-Reid S; Lipton JH
    Leuk Lymphoma; 2007 May; 48(5):1029-31. PubMed ID: 17487749
    [No Abstract]   [Full Text] [Related]  

  • 32. Doctors condemn NICE's guidance on leukaemia drug.
    Mayor S
    BMJ; 2002 Jun; 324(7350):1352. PubMed ID: 12052793
    [No Abstract]   [Full Text] [Related]  

  • 33. Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma.
    Mughal TI; Goldman JM
    Eur J Cancer; 2001 Mar; 37(5):561-8. PubMed ID: 11290430
    [No Abstract]   [Full Text] [Related]  

  • 34. Imatinib mesylate--gold standards and silver linings.
    Peggs K
    Clin Exp Med; 2004 Sep; 4(1):1-9. PubMed ID: 15598080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance.
    Sandoval C; Giamelli J; Jayabose S
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):507-8. PubMed ID: 12794534
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
    Murphy M; Close J; Lottenberg R; Rajasekhar A
    Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
    [No Abstract]   [Full Text] [Related]  

  • 37. Decrease of resistance to imatinib in leukaemia.
    Bakalova R; Zhelev Z; Ohba H
    Lancet; 2002 May; 359(9319):1776-7. PubMed ID: 12049890
    [No Abstract]   [Full Text] [Related]  

  • 38. Imatinib mesylate, the first molecularly targeted gene suppressor.
    Pindolia VK; Zarowitz BJ
    Pharmacotherapy; 2002 Oct; 22(10):1249-65. PubMed ID: 12389876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
    Conti RM; Padula WV; Larson RA
    Ann Hematol; 2015 Apr; 94 Suppl 2(0 2):S249-57. PubMed ID: 25814091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.